环索奈德鼻喷剂治疗季节性过敏性鼻炎疗效与安全的Meta分析

doi:10.6040/j.issn.1673-3770.0.2022.479

摘要/Abstract

摘要： 目的系统评价环索奈德鼻喷剂治疗季节性过敏性鼻炎的临床疗效和安全性,为临床合理用药提供循证依据。方法通过检索Cochrane library、Web of Science、Pubmed、ClinicalTrials、中国知网(CNKI)、万方、维普及中国生物医学数据库(CBM),收集比较环索奈德(试验组)和安慰剂(对照组)治疗过敏性鼻炎的随机对照试验,检索时限均为从建库至2022年10月。由2位评价员按照纳入及排除标准对文献进行严格筛选,并进行质量评估,使用RevMan5.4版软件进行统计分析。结果纳入8项研究的Meta分析结果显示,环索奈德具有降低瞬时总鼻症状评分［WMD=-0.43,95%CI(-0.63,-0.23),P<0.01］、瞬时鼻腔单项评分［WMD=-0.19,95%CI(-0.23,-0.05), P<0.01］、反映性总鼻症状评分［WMD=-0.66,95%CI(-0.80,-0.52),P<0.01］、反映性鼻腔单项评分［WMD=-0.23,95%CI(-0.26,-0.21),P<0.01］、瞬时眼部单项积分［WMD=-0.19,95%CI(-0.22,-0.15),P<0.01］、瞬时眼部症状总积分［WMD=-0.28,95%CI(-0.56,-0.00),P=0.05］、反映性眼部症状总积分［WMD=-0.27,95%CI(-0.54,-0.00),P=0.05］、反映性眼部单项积分［WMD=-0.17,95%CI(-0.21,-0.14),P<0.01］、鼻结膜炎生存质量量表［WMD=-0.61,95%CI(-0.76,-0.47),P<0.01］的相关评分的作用。试验组与对照组相比,不良反应事件的发生率［OR=0.96,95%CI(0.76,1.20),P=0.72］无变化。结论环索奈德鼻喷剂对季节性过敏性鼻炎的治疗卓有成效,且不良反应事件的发生率无变化,有良好的安全性及耐受性,具有进一步临床推广的价值。

关键词: 环索奈德, 过敏性鼻炎, Meta分析

Abstract: Objective This study aimed to evaluate the clinical efficacy and safety of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis and provide evidence-based guidelines for rational drug use. Methods Cochrane Library, Web of Science, PubMed, ClinicalTrials, China National Knowledge Infrastructure, WanFang, Chinese Scientific Journal, and Chinese Biomedical Databases were searched. Randomized controlled trials were collected to compare ciclesonide(trial groups)with placebo(control groups)for the treatment of allergic rhinitis. All RCTs were randomized from the establishment of the databases to October 2022. According to the inclusion and exclusion criteria, the literature was strictly screened by two evaluators. Additionally, the quality of the included studies was assessed. The Review Manager(version 5.4)software was used for statistical analyses. Results A total of 9 studies were included in this meta-analysis. In terms of efficacy, ciclesonide reduced instantaneous total nasal symptom score(weighted mean difference ［WMD］=-0.43; 95%convidence interval ［CI; -0.63,-0.23］; P<0.01)and instantaneous single nasal score ［WMD=-0.19; 95%CI(-0.23,-0.05); P<0.01］. Ciclesonide also reduced the role of reflective total nasal symptom score ［WMD=-0.66; 95%CI(-0.80,-0.52)］; P<0.01)and reflective nasal single score ［WMD=-0.23; 95%CI(-0.26,-0.21); P<0.01］. It also reduced instantaneous ocular symptom score ［WMD=-0.19; 95%CI ［-0.22,-0.15］; P<0.01］; instantaneous ocular symptom total score ［WMD=-0.28; 95%CI(-0.56,-0.00); P=0.05］; and reflective ocular symptom total score ［WMD=-0.27; 95%CI(-0.54,-0.00); P=0.05］. Moreover, ciclesonide reduced mirrored ocular single score ［WMD=-0.17; 95%CI(-0.21,-0.14); P<0.01］ and related scores of the rhinoconjunctivitis quality of life scale ［WMD=-0.61; 95%CI(-0.76,-0.47); P<0.01］. Regarding safety, the incidence of adverse events was not increased in the experimental group compared with the control group ［odds ratio=0.96; 95%CI(0.76,1.20); P=0.72］. Conclusion Ciclesonide nasal spray was effective in the treatment of seasonal allergic rhinitis. Furthermore, it did not increase the incidence of adverse events. Ciclesonide has been shown to have good safety and tolerance and the value of further clinical promotion.

Key words: Ciclesonide, Seasonal allergic rhinitis, Meta-analysis

中图分类号:

R765.21

张真,杨卓莹,周佳妮,张大为,陈仁杰. 环索奈德鼻喷剂治疗季节性过敏性鼻炎疗效与安全的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(1): 13-20.

ZHANG Zhen, YANG Zhuoying, ZHOU Jiani, ZHANG Dawei, CHEN Renjie. Efficacy and safety of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis:a Meta-analysis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(1): 13-20.

参考文献

[1] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 中国变应性鼻炎诊断和治疗指南(2022年,修订版)[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(2): 106-129. doi:10.3760/cma.j.cn115330-20211228-00828
[2] Zieglmayer P, Schmutz R, Lemell P, et al. Fast effectiveness of a solubilized low-dose budesonide nasal spray in allergic rhinitis[J]. Clinical & Experimental Allergy, 2020, 50(9): 1065-1077. doi:10.1111/cea.13691
[3] 李丽莎, 关凯, 李俊达, 等. 季节性变应性鼻炎预防治疗对患者生活质量的影响及相关转录组学研究[J]. 中华预防医学杂志, 2021, 55(5): 606-612. doi:10.3760/cma.j.cn112150-20210228-00198 LI Lisha, GUAN Kai, LI Junda, et al. The effect on patient life quality of prophylactic treatment to seasonal allergic rhinitis and related transcriptomics research[J]. Chinese Journal of Preventive Medicine, 2021, 55(5): 606-612. doi:10.3760/cma.j.cn112150-20210228-00198
[4] Sampieri G, Namavarian A, Lee JJW, et al. Hypothalamic-pituitary-adrenal axis suppression and intranasal corticosteroid use: a systematic review and meta-analysis[J]. International Forum of Allergy & Rhinology, 2022, 12(1): 11-27. doi:10.1002/alr.22863
[5] Damia Ski P, Kardas G, Panek M, et al. Improving the risk-to-benefit ratio of inhaled corticosteroids through delivery and dose: current progress and future directions[J]. Expert Opinion on Drug Safety, 2022, 21(4): 499-515. doi:10.1080/14740338.2022.1999926
[6] Duvignaud A, Lhomme E, Onaisi R, et al. Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial(COVERAGE)[J]. Clinical Microbiology and Infection: the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, 28(7): 1010-1016. doi:10.1016/j.cmi.2022.02.031
[7] Griesel M, Wagner C, Mikolajewska A, et al. Inhaled corticosteroids for the treatment of COVID-19[J]. The Cochrane Database of Systematic Reviews, 2022, 3(3): CD015125. doi:10.1002/14651858.CD015125
[8] Tsuji G, Nakajima S, Watashi K, et al. Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication[J]. Journal of Pharmacological Sciences, 2022, 149(3): 81-84. doi:10.1016/j.jphs.2022.04.001
[9] Ellaithy HM, Youssef A, Elhusseney SS, et al. Enhanced alveo pulmonary deposition of nebulized ciclesonide for attenuating airways inflammations: a strategy to overcome metered dose inhaler drawbacks[J]. Drug Delivery, 2021, 28(1): 826-843. doi:10.1080/10717544.2021.1905747
[10] Trevisiol S, Moulard Y, Kaadia Z, et al. LC-HRMS/MS study of the prodrug ciclesonide and its active metabolite desisobutyryl-ciclesonide in plasma after an inhalative administration to horses for doping control purposes[J]. Drug Testing and Analysis, 2022, 14(2): 252-261. doi:10.1002/dta.3174
[11] Qi Yang. The efficacy and safety of ciclesonide for the treatment of perennial allergic rhinitis: a systematic review and meta-analysis[J]. Brazilian Journal of Otorhinolaryngology, 2019, 85(3): 371-378. doi:10.1016/j.bjorl.2018.10.008
[12] Andrade C. Understanding the basics of meta-analysis and how to read a forest plot: As simple as it gets[J]. The Journal of Clinical Psychiatry, 2020, 81(5): 20f13698. doi:10.4088/JCP.20f13698
[13] Ratner P, Jacobs R, Mohar D, et al. Evaluation of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol, 80 or 160 μg once daily, for the treatment of seasonal allergic rhinitis[J]. Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology, 2010, 105(6): 471-479. doi:10.1016/j.anai.2010.09.024
[14] Craig MD. Efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol once daily for the treatment of seasonal allergic rhinitis[J]. Annals of Allergy, Asthma & Immunology, 2009, 103(2): 166-173. doi:10.1016/S1081-1206(10)60171-8
[15] Peter MD. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis[J]. Annals of Allergy, Asthma & Immunology, 2009, 102(1): 62-68. doi:10.1016/S1081-1206(10)60110-X
[16] Patel P, Patel D, Kunjibettu S, et al. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis[J]. Ear, Nose, & Throat Journal, 2008, 87(6): 340-353
[17] Ratner PH, Andrews C, Martin B, et al. A study of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol in patients with seasonal allergic rhinitis from mountain cedar pollen[J]. Allergy and Asthma Proceedings, 2012, 33(1): 27-35. doi:10.2500/aap.2012.33.3490
[18] Ratner PH, Wingertzahn MA, VAN BAVEL JH, et al. Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis[J]. Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology, 2006, 97(5): 657-663. doi:10.1016/S1081-1206(10)61097-6
[19] Effect of citrate on the coagulation system in patients receiving CRRT(citroco)[EB/OL].[2019-10-22]. https://clinicaltrials.gov/study/NCT02486614
[20] Efficacy and safety of ciclesonide nasal spray in participants with seasonal allergic rhinitis(SAR)in Russia)[EB/OL].[2019-10-22]. https://clinicaltrials.gov/ct2/show/ NCT01458275
[21] Bousquet J, Pfaar O, Togias A, et al. 2019 ARIA care pathways for allergen immunotherapy[J]. Allergy, 2019, 74(11): 2087-2102. doi:10.1111/all.13805
[22] Fu TT, Zhao Y, Yang FF, et al. Ciclesonide and budesonide suspensions for nebulization delivery: an in vivo inhalation biopharmaceutics investigation[J]. International Journal of Pharmaceutics, 2018, 549(1/2): 21-30. doi:10.1016/j.ijpharm.2018.07.048
[23] Jacobs RL. Ciclesonide for the treatment of seasonal allergic rhinitis[J]. Expert Review of Clinical Immunology, 2011, 7(6): 735-741. doi:10.1586/eci.11.70
[24] Humbert M. Ciclesonide: a novel inhaled corticosteroid[J]. Expert Opinion on Investigational Drugs, 2004, 13(10): 1349-1360. doi:10.1517/13543784.13.10.1349
[25] Mukker JK, Singh RSP, Derendorf H. Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids[J]. Journal of Pharmaceutical Sciences, 2016, 105(9): 2509-2514. doi:10.1016/j.xphs.2016.05.004
[26] 龚霄阳, 程雷. 新冠疫情期间基于门诊患者的变应性鼻炎患者比例构成分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 245-253. doi:10.6040/j.issn.1673-3770.0.2021.422 GONG Xiaoyang, CHENG Lei. Analysis of proportion of outpatients with allergic rhinitis during the coronavirus infectious disease 2019 pandemic[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 245-253. doi:10.6040/j.issn.1673-3770.0.2021.422
[27] Matsuyama S, Kawase M, Nao N, et al. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral replication-transcription complex in culture cells[J]. bioRxiv, 2020. doi: 10.1101/2020.08.22.258459. doi:10.1101/2020.08.22.258459
[28] Song JY, Yoog JG, Seo YB, et al. Ciclesonide inhaler treatment for mild-to-moderate COVID-19: a randomized, open-label, phase 2 trial[J]. Journal of Clinical Medicine, 2021, 10(16): 3545. doi:10.3390/jcm10163545
[29] Hsu DW, Suh JD. Anatomy and physiology of nasal obstruction[J]. Otolaryngologic Clinics of North America, 2018, 51(5): 853-865. doi:10.1016/j.otc.2018.05.001
[30] Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis executive summary[J]. Otolaryngolo Head Neck Surg, 2015, 152(2): 197-206. doi:10.1177/0194599814562166
[31] 杨钦泰, 陈建军, 谭国林, 等. 鼻用糖皮质激素治疗变应性鼻炎专家共识(2021, 上海)[J]. 中国耳鼻咽喉颅底外科杂志, 2021, 27(4): 365-371. doi:10.11798/j.issn.1007-1520.202140001 YANG Qintai, CHEN Jianjun, TAN Guolin, et al. Expert consensus on the management of allergic rhinitis with intranasal corticosteroid(2021, Shanghai)[J]. Chinese Journal of Otorhinolaryngology-Skull Base Surgery, 2021, 27(4): 365-371. doi:10.11798/j.issn.1007-1520.202140001
[32] Urdaneta E, Gates D. Effect of mometasone furoate nasal spray on moderate-to-severe nasal congestion in seasonal allergic rhinitis: a responder analysis[J]. Allergy and Asthma Proceedings, 2019, 40(3): 173-179. doi:10.2500/aap.2019.40.4214
[33] 刘英, 叶小静, 赵春丽, 等. 季节性变应性鼻炎预防性治疗观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 37-40. doi:10.6040/j.issn.1673-3770.0.2017.108 LIU Ying, YE Xiaojing, ZHAO Chunli, et al. Preventive treatment for seasonal allergic rhinitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2017, 31(3): 37-40. doi:10.6040/j.issn.1673-3770.0.2017.108

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed